SCHEMBL19083742

SCHEMBL19083742

CC(=O)NC(C(=O)O)C1CCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
NFKB1 P19838 1/20 0.36
PTGS2 P35354 1/20 0.36
THPO P40225 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
PYGL P06737 4/20 0.35
KMT2A Q03164 2/20 0.35
MMP2 P08253 4/20 0.35
MMP1 P03956 3/20 0.35
MMP3 P08254 2/20 0.35
MMP7 P09237 1/20 0.35
MMP13 P45452 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19083902 1.00 SMN1; SMN2 (0.37) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL10445869 0.96 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL10442216 0.96 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL6885724 0.94 MMP2 (0.41) SMN1; SMN2ALDH1A1PYGLKMT2AMMP2
SCHEMBL3285856 0.94 MMP2 (0.41) SMN1; SMN2ALDH1A1PYGLKMT2AMMP2
SCHEMBL329758 0.94 MMP2 (0.41) SMN1; SMN2ALDH1A1PYGLKMT2AMMP2
SCHEMBL31730569 0.91 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL13544389 0.91 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL19083735 0.91 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB
SCHEMBL9800440 0.82 KDM4E (0.33) SMN1; SMN2ALDH1A1KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 US disclosed
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-03-18 US disclosed
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 EP disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SMN1; SMN2 2803/4885ALDH1A1 1155/4885KDM4E 2958/4885
US-11149002-B2 Therapeutic compounds and methods of use thereof RDX, C1R, MTX1 SMN1; SMN2 2803/4885ALDH1A1 1155/4885KDM4E 2958/4885
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SMN1; SMN2 2803/4885ALDH1A1 1155/4885KDM4E 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.